Table 3. . Anti-CD19 chimeric antigen receptor T-cell therapy: combination studies in diffuse large B-cell lymphoma.
| CAR T product | Indication | Agents | Phase | NCT N |
|---|---|---|---|---|
| Axi-cel (ZUMA-6) | R/R DLBCL | Atezolizumab | I/II | NCT02926833 |
| Axi-cel (ZUMA-11) | R/R DLBCL | Utomilumab | I/Ib | NCT03704298 |
| Axi-cel (ZUMA-14) | R/R DLBCL | Lenalidomide and rituximab | I/Ib | NCT04002401 |
| Tisa-cel | R/R DLBCL | Ibrutinib | Ib | NCT03876028 |
| Tisa-cel (PORTIA) | R/R DLBCL | Pembrolizumab | Ib | NCT03630159 |
| Liso-cel (PLATFORM) | R/R DLBCL | CC-122, durvalumab, ibrutinib | I/II | NCT03310619 |
DLBCL: Diffuse large B-cell lymphoma.